Search research articles
Contact Us
Filters
Showing results (1-10 of 70) with videos related to
Page
of 7
Sort By:
Cold Spring Harbor Perspectives in Medicine
|
January 8, 2023
Emerging Therapies for Breast Cancer
Shom Goel, Sarat Chandarlapaty
Immunology and Cell Biology
|
December 6, 2020
Transforming growth factor β in breast cancer: another new trick for the old dog
Kun-Hui Lu, Shom Goel
Oncotarget
|
July 9, 2016
CDK4/6 inhibition: the late harvest cycle begins
Shom Goel, Jean J Zhao
Breast Cancer Research : BCR
|
March 6, 2022
Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer
April C Watt, Shom Goel
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 30, 2010
Troponin I as a predictor for trastuzumab-related cardiotoxicity: current data do not provide mechanistic insights or allow for incorporation into clinical practice
Shom Goel, Jane M Beith
The Lancet. Oncology
|
October 3, 2019
CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?
Shom Goel, Sara M Tolaney
Oncology (Williston Park, N.Y.)
|
November 18, 2015
POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer
Shom Goel, Eric P Winer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2015
Deciphering the role of phosphatidylinositol 3-kinase mutations in human epidermal growth factor receptor 2-positive breast cancer
Shom Goel, Ian E Krop
Current Breast Cancer Reports
|
May 9, 2017
CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure
Ana C Garrido-Castro, Shom Goel
Translational Cancer Research
|
February 4, 2022
Trastuzumab-related cardiotoxicity: what do we know in 2020?
Jia Liu, Shom Goel, Jane McNeil Beith
Page
of 7
Search research articles
Search
Showing results (1-10 of 70) with videos related to
Sort By:
Page
of 7
Cold Spring Harbor Perspectives in Medicine
|
January 8, 2023
Emerging Therapies for Breast Cancer
Shom Goel, Sarat Chandarlapaty
Immunology and Cell Biology
|
December 6, 2020
Transforming growth factor β in breast cancer: another new trick for the old dog
Kun-Hui Lu, Shom Goel
Oncotarget
|
July 9, 2016
CDK4/6 inhibition: the late harvest cycle begins
Shom Goel, Jean J Zhao
Breast Cancer Research : BCR
|
March 6, 2022
Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer
April C Watt, Shom Goel
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 30, 2010
Troponin I as a predictor for trastuzumab-related cardiotoxicity: current data do not provide mechanistic insights or allow for incorporation into clinical practice
Shom Goel, Jane M Beith
The Lancet. Oncology
|
October 3, 2019
CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?
Shom Goel, Sara M Tolaney
Oncology (Williston Park, N.Y.)
|
November 18, 2015
POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer
Shom Goel, Eric P Winer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2015
Deciphering the role of phosphatidylinositol 3-kinase mutations in human epidermal growth factor receptor 2-positive breast cancer
Shom Goel, Ian E Krop
Current Breast Cancer Reports
|
May 9, 2017
CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure
Ana C Garrido-Castro, Shom Goel
Translational Cancer Research
|
February 4, 2022
Trastuzumab-related cardiotoxicity: what do we know in 2020?
Jia Liu, Shom Goel, Jane McNeil Beith
Page
of 7